

## ASX ANNOUNCEMENT

### CONFIRMING CHANGES TO THE CELLMID BOARD

**SYDNEY, Thursday, 24 December 2020: Cellmid Limited (ASX: CDY)** wishes to confirm changes to its Board.

On 21 October 2020 Cellmid advised the ASX that independent chairman, Dr David King, will leave the Board on 31 December 2020. The temporary extension of Dr King's tenure assisted in an orderly transition and the new independent chairman, Mr Bruce Gordon, will take over from 1 January 2021. Mr Gordon will also chair the Company's Nomination and Remuneration Committee from 1 January 2020, while relinquishing his role as Chair of the Audit Committee to Dr Martin Cross.

Cellmid's pivot into a beauty-tech company with deep expertise in hair biology, clinically validated products, a loyal customer base, leading social and digital capability and a rapidly growing global distribution network has been completed during 2020. Its board of directors with expertise in retail, marketing and finance are expected to propel the company on its growth path in 2021 and beyond. Dr King's leadership has resulted in a Company that is well set on the path for future growth. The directors of Cellmid wish to thank David for his outstanding service and commitment to the Company.


Approved for release by the Board of Directors of Cellmid.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

#### **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au). Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently Cellmid secured access to a range of SARS-CoV-2 antibody and nucleotide tests, both point of care and laboratory based, from various suppliers.

#### **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.